Cagrilintide vs Semaglutide: Research Compared
A side by side look at two metabolic research compounds, one an investigational amylin analogue and one an approved GLP-1 receptor agonist, at the mechanism and trial level. General information only, not legal or medical advice.
The short answer
Cagrilintide and semaglutide are two different classes of molecule that appear frequently in the same metabolic and appetite regulation literature. Cagrilintide is a long acting amylin analogue (also referenced as AM833) developed by Novo Nordisk and, as of 2026, it remains investigational and is studied largely in combination rather than as a standalone approved product. Semaglutide is a GLP-1 receptor agonist that is an approved prescription medicine in Australia and is listed on the Australian Register of Therapeutic Goods. This guide compares the two at the level of mechanism and trial design only. It does not rank them, make efficacy claims, or offer any human use guidance.
Treat every statement here as background literature, not advice. Where a compound is described as being studied or investigated for something, that means it appears in research, not that any outcome is established or recommended for any person.
Two different drug classes
The core distinction is pharmacological class. Semaglutide belongs to the glucagon like peptide 1 (GLP-1) receptor agonist family. Cagrilintide is an amylin analogue, meaning it is designed to resemble the hormone amylin rather than GLP-1. Because they target different receptor systems, they are often discussed as complementary research tools rather than direct substitutes.
This difference in class also explains why the two are frequently studied together. A co formulation of cagrilintide and semaglutide, referred to in the literature as CagriSema, has been investigated specifically because the two act on separate pathways involved in appetite and metabolic signalling.
Cagrilintide: the amylin pathway
Amylin is a hormone co secreted with insulin from the pancreas. In the research literature, amylin signalling is studied in the context of satiety, gastric emptying and glucose regulation. Cagrilintide is engineered as a long acting analogue of amylin, intended to extend activity over a longer interval than the native hormone, which is why it is described in papers as a once weekly candidate in trial settings.
Cagrilintide is identified in sources under the development code AM833. It is an investigational compound. Published descriptions place its standalone development within early and mid stage clinical research, while the more advanced programs focus on the combination with semaglutide.
Cagrilintide is not listed on the Australian Register of Therapeutic Goods as a standalone approved product. It should be treated as an investigational research compound, not a registered medicine.
Semaglutide: the GLP-1 pathway
Semaglutide acts on the GLP-1 receptor. GLP-1 is an incretin hormone, which in the physiology literature is linked to glucose dependent insulin signalling, gastric emptying and appetite related pathways. Because of this incretin context, semaglutide is discussed in both metabolic and glucose regulation research, giving it a slightly broader literature footprint than an amylin analogue alone.
Unlike cagrilintide, semaglutide is an approved medicine in Australia. It is listed on the Australian Register of Therapeutic Goods and is a Schedule 4 (prescription only) substance. Approved branded products containing semaglutide are available in Australia under prescription from a registered practitioner.
Approved medicine vs research material
An important distinction runs through this whole comparison. When semaglutide is referenced as an approved medicine, that refers to the registered, prescription pharmaceutical product supplied through regulated channels. Any material supplied by this store is research use only and is distinct from that approved medicine. It is not a substitute for a prescription product and is not intended for human use.
Cagrilintide, by contrast, has no standalone approved equivalent in Australia, so any reference to it here is purely to the investigational literature. In both cases the framing is the same: research context only.
Materials discussed on this site are intended for laboratory research use only. Nothing here describes or endorses human use, dosing, or any therapeutic application.
Trial design at a neutral level
At a factual level, the two compounds sit at very different points in the development pathway. Semaglutide has completed the regulatory process required for an approved medicine in Australia. Cagrilintide remains investigational, and the most advanced published programs study it inside the CagriSema combination rather than on its own.
Novo Nordisk has run clinical trials examining cagrilintide both alone and together with semaglutide, including combination work that advanced through later phase development. We describe this only to locate each compound on the research timeline. We make no comparison of outcomes and no claim that either compound produces any specific result.
Where each sits in the literature
- Semaglutide: an approved, ARTG listed GLP-1 receptor agonist with an established clinical record
- Cagrilintide: an investigational amylin analogue (AM833), studied alone and in combination
- CagriSema: the cagrilintide plus semaglutide co formulation studied because the two act on separate pathways
How to read claims about either compound
Metabolic research compounds attract a lot of online commentary, and not all of it is accurate. When you encounter a strong statement about cagrilintide or semaglutide, it helps to ask what the source is, whether it refers to an approved product or an investigational compound, and whether the claim is describing published research or simply repeating marketing language.
Being studied for something is not the same as being proven to do it, and being approved as a medicine is not the same as being available for research use.
Keeping those distinctions clear is the single most useful habit when comparing a registered medicine against an investigational analogue.
Summary of the comparison
In short, cagrilintide and semaglutide are often mentioned together but are not the same kind of molecule. Semaglutide is a GLP-1 receptor agonist and an approved, prescription only, ARTG listed medicine in Australia. Cagrilintide is an investigational long acting amylin analogue with no standalone approval, studied largely in combination as CagriSema. Any material supplied by this store is research use only and separate from any approved medicine. This guide is a neutral literature overview and nothing more.
Frequently asked questions
Is cagrilintide approved in Australia?+
No. Cagrilintide is an investigational amylin analogue and, as of 2026, it is not listed on the Australian Register of Therapeutic Goods as a standalone approved product. It is studied largely in combination with semaglutide in the CagriSema program. This is general information only, not legal or medical advice.
Is semaglutide approved in Australia?+
Semaglutide is a GLP-1 receptor agonist that is an approved medicine in Australia, listed on the Australian Register of Therapeutic Goods and classified as Schedule 4, meaning prescription only. The approved medicine is distinct from any research use only material.
What is the main mechanism difference between the two?+
Semaglutide acts on the GLP-1 receptor, part of the incretin system linked in research to glucose and appetite signalling. Cagrilintide is an amylin analogue, acting on the amylin pathway instead. They target different receptor systems, which is why they are often studied together.
What is CagriSema?+
CagriSema is the name used in the literature for a co formulation combining cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist). It has been studied because the two compounds act on separate pathways involved in metabolic and appetite regulation.
What does AM833 refer to?+
AM833 is a development code used in the literature for cagrilintide. Seeing AM833 in a paper or listing is simply another way of referring to the same investigational amylin analogue.
Which one is better?+
This guide does not rank the two compounds or make efficacy claims. They are different classes at different stages of development, one approved and one investigational, and are presented here only as a neutral research comparison.
Is the material sold here a medicine?+
No. Any material supplied by this store is research use only and is distinct from any approved, prescription medicine. It is not intended for human use and nothing here constitutes medical advice.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp